A PPAR-β/γ agonist is neuroprotective and decreases cognitive impairment in a rodent model of parkinson's disease

Current Neurovascular Research

Volumn 11, Issue 2, 2014, Pages 114-124

  Das, Nihar R ^a   Gangwal, Rahul P ^b   Damre, Mangesh V ^b   Sangamwar, Abhay T ^b   Sharma, Shyam S ^a  

^a Molecular Neuropharmacology Laboratory Department of Pharmacology and Toxicology   (India)

^b NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

GastroPlus; GW0742; MPTP; Parkinson's disease; PBPK modeling; PPAR beta

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; GLUTATHIONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST; TYROSINE 3 MONOOXYGENASE; [4 [2 (3 FLUORO 4 TRIFLUOROMETHYLPHENYL) 4 METHYL 5 THIAZOLYLMETHYLTHIO] 2 METHYLPHENOXY]ACETIC ACID; NEUROPROTECTIVE AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; THIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG BLOOD LEVEL; MALE; MORRIS WATER MAZE TEST; NERVE CELL; NEUROPROTECTION; NICK END LABELING; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PASSIVE AVOIDANCE; PRIORITY JOURNAL; RAT; RODENT MODEL; AGONISTS; ANIMAL; BRAIN; COGNITION; DISEASE MODEL; DRUG EFFECTS; MAZE TEST; METABOLISM; PARKINSONISM; SPRAGUE DAWLEY RAT; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; BRAIN; COGNITION; DISEASE MODELS, ANIMAL; DNA FRAGMENTATION; IN SITU NICK-END LABELING; MALE; MAZE LEARNING; NEURONS; NEUROPROTECTIVE AGENTS; PARKINSONIAN DISORDERS; PPAR DELTA; PPAR-BETA; RATS; RATS, SPRAGUE-DAWLEY; THIAZOLES;

EID: 84900553265     PISSN: 15672026     EISSN: 18755739     Source Type: Journal    
DOI: 10.2174/1567202611666140318114037     Document Type: Article

References (60)

1. Sprenger F, Poewe W. Management of Motor and Non-Motor Symptoms in Parkinson's Disease. CNS Drugs 2013: 1-14.
2. Taylor JM, Main BS, Crack PJ. Neuroinflammation and oxidative stress: Co-conspirators in the pathology of Parkinson's disease. Neurochem Int 2013; 62(5): 803-19.
3. Exner N, Lutz AK, Haass C, Winklhofer KF. Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences. EMBO J 2012; 31(14): 3038-62.
4. Blandini F. An update on the potential role of excitotoxicity in the pathogenesis of Parkinson's disease. Funct Neurol 2010; 25(2): 65-71.
5. Hwang O. Role of Oxidative Stress in Parkinson's Disease. Exp Neurobiol 2013; 22(1): 11-17.
6. Yokoyama H, Kuroiwa H, Yano R, Araki T. Targeting reactive oxygen species, reactive nitrogen species and inflammation in MPTP neurotoxicity and Parkinson's disease. Neurol Sci 2008; 29(5): 293-301.
7. Williams-Gray CH, Foltynie T, Lewis SJ, Barker RA. Cognitive Deficits and Psychosis in Parkinson's Disease. CNS Drugs 2006; 20(6): 477-505.
8. Palavra NC, Naismith SL, Lewis SJ. Mild Cognitive Impairment in Parkinson's disease: A review of current concepts. Neurol Res Int 2013; 2013. doi:10.1155/2013/576091.
9. Fernandez HH, Crucian GP, Okun MS, Price CC, Bowers D. Mild cognitive impairment in Parkinson's disease: the challenge and the promise. Neuropsychiatr Dis Treat 2005; 1(1): 37.
10. Brown JD, Plutzky J. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation 2007; 115(4): 518-33.
11. Kumar P, Kaundal RK, More S, Sharma SS. Beneficial effects of pioglitazone on cognitive impairment in MPTP model of Parkinson's disease. Behav Brain Res 2009; 197(2): 398-403.
12. Schnegg CI, Robbins ME. Neuroprotective mechanisms of PPAR-: modulation of oxidative stress and inflammatory processes. PPAR Res 2011; 2011. doi:10.1155/2011/373560.
13. Woods JW, Tanen M, Figueroa DJ, et al. Localization of PPAR beta in murine central nervous system: expression in oligodendrocytes and neurons. Brain Res 2003; 975(1): 10-21.
14. Kilgore KS, Billin AN. PPARbeta/delta ligands as modulators of the inflammatory response. Curr Opin Investig Drugs 2008; 9(5): 463-69.
15. Kuang G, He Q, Zhang Y, et al. Modulation of Preactivation of PPAR-beta on Memory and Learning Dysfunction and Inflammatory Response in the Hippocampus in Rats Exposed to Global Cerebral Ischemia/Reperfusion. PPAR Research 2012; 2012.
16. Di Paola R, Esposito E, Mazzon E, Paterniti I, Galuppo M, Cuzzocrea S. GW0742, a selective PPAR-/-agonist, contributes to the resolution of inflammation after gut ischemia/reperfusion injury. J Leukoc Biol 2010; 88(2): 291-301.
17. Iwashita A, Muramatsu Y, Yamazaki T, et al. Neuroprotective efficacy of the peroxisome proliferator-activated receptor deltaselective agonists in vitro and in vivo. J Pharmacol Exp Ther 2007; 320(3): 1087-96.
18. Polak PE, Kalinin S, Dello Russo C, et al. Protective effects of a peroxisome proliferator-activated receptor-/-agonist in experimental autoimmune encephalomyelitis. J Neuroimmunol 2005; 168(1): 65-75.
19. Kalinin S, Richardson JC, Feinstein DL. A PPARdelta agonist reduces amyloid burden and brain inflammation in a transgenic mouse model of Alzheimer's disease. Curr Alzheimer Res 2009; 6(5): 431-37.
20. Barbiero JK, Santiago RM, Lima M, et al. Acute but not chronic administration of pioglitazone promoted behavioral and neurochemical protective effects in the MPTP model of Parkinson's disease. Behav Brain Res 2011; 216(1): 186-92.
21. Da Cunha C, Wietzikoski S, Wietzikoski EC, et al. Pre-training to find a hidden platform in the Morris water maze can compensate for a deficit to find a cued platform in a rat model of Parkinson's disease. Neurobiol Learn Mem 2007; 87(4): 451-63.
22. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. 3rd. ed. San Diego: Academic Press 1997.
23. Uppalapati D, Das NR, Gangwal RP, Damre MV, Sangamwar A, Sharma SS. Neuroprotective Potential of Peroxisome Proliferator Activated receptor-(PPAR-) agonist in cognitive impairment in Parkinson's disease: Behavioral, biochemical and PBPK profile. PPAR Res 2014; 2014. doi:10.1155/2014/753587
24. Ferro MM, Bellissimo MI, Anselmo-Franci JA, Angellucci MEM, Canteras NS, Da Cunha C. Comparison of bilaterally 6-OHDA-and MPTP-lesioned rats as models of the early phase of Parkinson's disease: histological, neurochemical, motor and memory alterations. J Neurosci Methods 2005; 148(1): 78-87.
25. Sonkusare S, Srinivasan K, Kaul C, Ramarao P. Effect of donepezil and lercanidipine on memory impairment induced by intracerebroventricular streptozotocin in rats. Life Sci 2005; 77(1): 1-14.
26. Pathan AR, Viswanad B, Sonkusare SK, Ramarao P. Chronic administration of pioglitazone attenuates intracerebroventricular streptozotocin induced-memory impairment in rats. Life Sci 2006; 79(23): 2209-16.
27. Vorhees CV, Williams MT. Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat Protoc 2006; 1(2): 848-58.
28. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979; 95(2): 351-58.
29. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193(1): 265-75.
30. Moron MS, Depierre JW, Mannervik B. Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liver. Biochimica et Biophysica Acta (BBA)-General Subjects 1979; 582(1): 67-78.
31. Rahman I, Kode A, Biswas SK. Assay for quantitative determination of glutathione and glutathione disulfide levels using enzymatic recycling method. Nat Protoc 2007; 1(6): 3159-65.
32. Kabra DG, Thiyagarajan M, Kaul CL, Sharma SS. Neuroprotective effect of 4-amino-1, 8-napthalimide, a poly (ADP ribose) polymerase inhibitor in middle cerebral artery occlusion-induced focal cerebral ischemia in rat. Brain Res Bull 2004; 62(5): 425-33.
33. Thiyagarajan M, Kaul CL, Sharma SS. Neuroprotective efficacy and therapeutic time window of peroxynitrite decomposition catalysts in focal cerebral ischemia in rats. Br J Pharmacol 2004; 142(5): 899-911.
34. Kaundal RK, Shah KK, Sharma SS. Neuroprotective effects of NU1025, a PARP inhibitor in cerebral ischemia are mediated through reduction in NAD depletion and DNA fragmentation. Life Sci 2006; 79(24): 2293-302.
35. Kumar A, Sharma SS. NF-kB inhibitory action of resveratrol: A probable mechanism of neuroprotection in experimental diabetic neuropathy. Biochem Biophys Res Commun 2010; 394(2): 360-65.
36. Rodríguez-Gómez JA, Romero-Ramos M, Vizuete ML, Venero JL, Cano J, Machado A. Increased activity and expression of tyrosine hydroxylase in the rat substantia nigra after chronic treatment with nomifensine. Mol Pharmacol 1997; 52(4): 641-47.
37. GastroPlus, Version 85, Simulations Inc, Lancaster, California 93534-7059 • USA, 2013.
38. De Buck SS, Sinha VK, Fenu LA, Nijsen MJ, Mackie CE, Gilissen RA. Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs. Drug Metab Dispos 2007; 35(10): 1766-80.
39. Parrott N, Paquereau N, Coassolo P, Lavé T. An evaluation of the utility of physiologically based models of pharmacokinetics in early drug discovery. J Pharm Sci 2005; 94(10): 2327-43.
40. Da Cunha C, Gevaerd MS, Vital MABF, et al. Memory disruption in rats with nigral lesions induced by MPTP: a model for early Parkinson's disease amnesia. Behav Brain Res 2001; 124(1): 9-18.
41. Perry JC, Da Cunha C, Anselmo-Franci J, et al. Behavioural and neurochemical effects of phosphatidylserine in MPTP lesion of the substantia nigra of rats. Eur J Pharmacol 2004; 484(2-3): 225-33.
42. Sarkar S, Raymick J, Mann D, et al. Neurovascular Changes in Acute, sub-Acute and Chronic Mouse Models of Parkinson's Disease. Curr Neurovasc Res 2014; 11(1): 48-61.
43. Breidert T, Callebert J, Heneka M, Landreth G, Launay J, Hirsch E. Protective action of the peroxisome proliferator activated receptor agonist pioglitazone in a mouse model of Parkinson's disease. J Neurochem 2002; 82(3): 615-24.
44. Kaundal RK, Sharma SS. Peroxisome proliferator-activated receptor gamma agonists as neuroprotective agents. Drug News Perspect 2010; 23(4): 241.
45. Landreth G, Jiang Q, Mandrekar S, Heneka M. PPAR-agonists as therapeutics for the treatment of Alzheimer's disease. Neurotherapeutics 2008; 5(3): 481-89.
46. Lawlor PA, Bland RJ, Das P, et al. Novel rat Alzheimer's disease models based on AAV-mediated gene transfer to selectively increase hippocampal Abeta levels. Mol Neurodegener 2007; 2(11): 17501326-211.
47. Sarkaki A, Rezaiei M, Naseri MG, Rad MR. Improving Active and Passive Avoidance Memories Deficits Due to Permanent Cerebral Ischemia by Pomegranate Seed Extract in Female Rats. Malays J Med Sci 2013; 20(2): 25-34.
48. Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 1984; 11(1): 47-60.
49. Ilic TV, Jovanovic M, Jovicic A, Tomovic M. Oxidative stress indicators are elevated in de novo Parkinson's disease patients. Funct Neurol 1999; 14(3): 141.
50. Janero DR. Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and peroxidative tissue injury. Free Radic Biol Med 1990; 9(6): 515-40.
51. Sofic E, Lange KW, Jellinger K, Riederer P. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci Lett 1992; 142(2): 128-30.
52. Jagatha B, Mythri RB, Vali S, Bharath MM. Curcumin treatment alleviates the effects of glutathione depletion in vitro and in vivo: therapeutic implications for Parkinson's disease explained via in silico studies. Free Radic Biol Med 2008; 44(5): 907-17.
53. Lindgren N, Goiny M, Herrera-Marschitz M, Haycock JW, Hökfelt T, Fisone G. Activation of extracellular signal-regulated kinases 1 and 2 by depolarization stimulates tyrosine hydroxylase phosphorylation and dopamine synthesis in rat brain. Eur J Neurosci 2002; 15(4): 769-73.
54. Costa RM, Lin S-C, Sotnikova TD, et al. Rapid alterations in corticostriatal ensemble coordination during acute dopaminedependent motor dysfunction. Neuron 2006; 52(2): 359-69.
55. Matsumoto M, Takada M. Distinct Representations of Cognitive and Motivational Signals in Midbrain Dopamine Neurons. Neuron 2013; 79(5): 1011-24.
56. Capitelli C, Sereniki A, Lima MMS, Reksidler AB, Tufik S, Vital MABF. Melatonin attenuates tyrosine hydroxylase loss and hypolocomotion in MPTP-lesioned rats. Eur J Pharmacol 2008; 594(1-3): 101-08.
57. Liu L, Arun A, Ellis L, Peritore C, Donmez G. Sirtuin 2 (SIRT2) enhances 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-induced nigrostriatal damage via deacetylating forkhead box O3a (Foxo3a) and activating Bim protein. J Biol Chem 2012; 287(39): 32307-11.
58. Serra PA, Sciola L, Delogu MR, et al. The Neurotoxin 1-Methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine Induces Apoptosis in Mouse Nigrostriatal Glia Relevance to Nigral Neuronal death and Striatal Neurochemical Changes. J Biol Chem 2002; 277(37): 34451-61.
59. Jones HM, Gardner IB, Watson KJ. Modelling and PBPK simulation in drug discovery. The AAPS J 2009; 11(1): 155-66.
60. Sznaidman ML, Haffner CD, Maloney PR, et al. Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPAR delta)-synthesis and biological activity. Bioorg Med Chem Lett 2003; 13(9): 1517-21.